Benitec Biopharma Inc.

# Signal Note: RA Capital initiates $24.9M position in BNTC RA Capital's entry into Benitec signals conviction in its RNA interference pipeline, notably BB-301 for transthyretin amyloidosis (ATTR), which offers potentially differentiated durability versus approved competitors through hepatic-targeted RNAi. The $24.9M stake (representing ~6.5% diluted) likely reflects positioning ahead of upcoming clinical data; BB-301 Phase 2b readout timing and regulatory pathway clarity will be near-term catalysts. Given RA Capital's track record in RNA therapeutics, this suggests internal confidence in Benitec's technical execution and competitive positioning in the crowded ATTR space.